Bupivacaine
Marcaine · Sensorcaine
Amide local anesthetic, long-acting
Voltage-gated Na⁺ channel blocker. Higher protein binding and lipid solubility than lidocaine → longer duration but greater cardiotoxicity.
Indications
- •Spinal/epidural
- •Peripheral nerve blocks
- •Wound infiltration
Dosing
| Context | Adult | Pediatric |
|---|---|---|
| Local infiltration | Max 2.5 mg/kg plain; 3 mg/kg with epi | — |
| Spinal anesthesia | 0.5% hyperbaric 7.5–15 mg | — |
| Epidural | 0.25–0.5% 10–20 mL bolus, 0.0625–0.125% 4–10 mL/hr infusion | — |
| Peripheral block | 0.25–0.5% 20–40 mL | — |
Pharmacokinetics
Onset 5–15 min. Duration 4–8 h. Hepatic CYP3A4.
Side effects
- !LAST — bupivacaine more cardiotoxic than equipotent lidocaine; ventricular arrhythmias dominate over CNS prodrome
- !TNS rare (vs. lidocaine)
- !Maternal hypotension after spinal (sympathectomy)
Contraindications
- ×IV regional anesthesia (use lidocaine)
- ×Bier block — never bupivacaine
Reversal / antidote
If LAST: lipid emulsion 20% 1.5 mL/kg bolus + 0.25 mL/kg/min infusion. Modified ACLS (low-dose epi).
Clinical pearls
- ★Liposomal bupivacaine (Exparel) — single-injection 24–72 h analgesia for surgical infiltration / TAP / interscalene.
- ★Avoid mixing with lidocaine in same syringe — pharmacokinetics unpredictable.
- ★Lipid rescue more for bupi than ropi or lidocaine.
Education only — confirm against current package inserts and institutional protocols. Doses assume normal organ function unless otherwise noted.